NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC:PRWP) today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.
